Industrial Pharmacist salary analysis

High — India accounts for ~20% of global generic drug volume by quantity and ~30% of US generics by prescriptions dispensed. USFDA-approved Indian manufacturing sites grew from 160 in 2010 to 300+ in 2025, and the biosimilar, CDMO, and API sectors are in a structurally expansionary phase. Revised Schedule M (2023) enforcement across all Indian pharma manufacturers is creating massive demand for cGMP-trained industrial pharmacists — the compliance gap between large and mid-tier Indian pharma sites is the career opportunity for the next decade. Global pharma supply-chain diversification away from China (API sector) is also driving capacity expansions at Divi's, Aurobindo, Laurus Labs, and Aarti Drugs.

₹35.0 LPA